New Zealand markets close in 5 hours 53 minutes

Bio-Techne Corporation (TECH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
80.41-2.57 (-3.10%)
At close: 04:00PM EDT
82.07 +1.66 (+2.06%)
After hours: 07:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close82.98
Open82.32
Bid80.33 x 100
Ask80.52 x 300
Day's range79.77 - 83.96
52-week range51.79 - 89.91
Volume745,982
Avg. volume1,133,614
Market cap12.671B
Beta (5Y monthly)1.23
PE ratio (TTM)64.33
EPS (TTM)1.25
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yield0.32 (0.39%)
Ex-dividend date10 May 2024
1y target est83.52
  • Insider Monkey

    Multiple Headwinds Dragged Bio-Techne Corp. (TECH) in Q1

    Conestoga Capital Advisors, an asset management company, released its “Mid-Cap Strategy” first-quarter 2024 investor letter. A copy of the letter can be downloaded here. It was a solid quarter as many asset classes moved higher. The S&P Index, which tracks the performance of large-cap stocks, reached an all-time high on March 28th, and the Russell 2000 […]

  • PR Newswire

    BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE

    Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 8:40 a.m. CDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

  • PR Newswire

    BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY

    Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The two companies began t